MARKET

PDSB

PDSB

PDS Biotechnology Corporation
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7000
+0.0284
+4.23%
Opening 11:25 04/06 EDT
OPEN
0.6549
PREV CLOSE
0.6716
HIGH
0.7400
LOW
0.6405
VOLUME
54.95K
TURNOVER
--
52 WEEK HIGH
9.45
52 WEEK LOW
0.6153
MARKET CAP
10.70M
P/E (TTM)
-0.6015
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PDSB stock price target is 7.73 with a high estimate of 10.00 and a low estimate of 5.45.

EPS

PDSB News

More
  • The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
  • Benzinga · 3d ago
  • PDS Biotechnology (PDSB) Upgraded to Buy: What Does It Mean for the Stock?
  • Zacks · 3d ago
  • Benzinga's Top Upgrades, Downgrades For March 30, 2020
  • Benzinga · 03/30 13:35
  • H.C. Wainwright Downgrades PDS Biotechnology to Neutral, Removes $7 Price Target
  • Benzinga · 03/30 11:21

Industry

Biotechnology & Medical Research
+3.76%
Pharmaceuticals & Medical Research
+3.03%

Hot Stocks

Symbol
Price
%Change

About PDSB

PDS Biotechnology Corp, formerly Edge Therapeutics, Inc., is an immuno-oncology company, The Company is focused on developing a pipeline of clinical-stage immunotherapies. Its therapies are developed for the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Versamune is its synthetic lipid-based immunotherapy platform. Its lead product candidate, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. Its pipeline also includes PDS0102, PDS0103 and PDS0104. Its pipeline of Versamune-based products are all administered by subcutaneous injection .DS0102 is being developed for the treatment of prostate and breast cancers. PDS0103 is based on novel agonist antigens of the mucin-1 (MUC-1) oncogenic C-terminal region. PDS0104 is being developed for the treatment of melanoma.
More

Webull offers kinds of PDS Biotechnology Corp stock information, including NASDAQ:PDSB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PDSB stock news, and many more online research tools to help you make informed decisions.